A Mayo Clinic analysis of more than 1,400 early‑stage pancreatic cancer patients found that administering chemotherapy before surgery (neoadjuvant therapy) significantly improved overall survival versus the traditional surgery-first approach. The multicenter retrospective study covered cases across Mayo Clinic campuses and assessed long‑term outcomes tied to sequencing decisions. Authors suggest the findings should prompt reconsideration of standard treatment pathways and inform prospective trials. The data add to a growing body of evidence favoring multimodal neoadjuvant strategies for resectable pancreatic tumors.